COMMUNIQUÉS West-GlobeNewswire
-
Avacta Achieves Clinical Proof of Mechanism for the Next Generation of pre|CISION® Medicines with AVA6103 (FAP-Exd) in the Phase 1 FOCUS-01 Trial
16/09/2026 -
TerrAscend Strengthens Leadership Position in New Jersey with Closing of Aunt Mary’s Transaction
16/09/2026 -
Dr. Peter Goldman Returns to the Bay Area, Bringing Zone Technique and a Distinct Approach to Healing to Berkeley, CA
16/09/2026 -
X-Chem Named First Winner of Chordoma Foundation TBXT Challenge with Discovery of Novel Binder for Untreatable Bone Cancer Target
16/09/2026 -
NEXGEL Announces Date for Investor Update Call
16/09/2026 -
PETVIVO ANIMAL HEALTH, INC. RELEASES CONFERENCE AND EXHIBIT SCHEDULE FOR 2026-2027
16/09/2026 -
Impact Biomedical Inc Announces Filing of Form F-4 Registration Statement in Connection with Proposed Merger with Zoar Ltd. (f/k/a Dr. Ashley’s Limited)
16/09/2026 -
NeurAxis Announces Medical Coverage Policy Milestone, Expanding Access to Over 18 million additional Covered Lives
16/09/2026 -
NeuroSigma Expands Payment Options for the Monarch eTNS® System
16/09/2026 -
Milestone Scientific Announces Pain and Spine Specialists and Dr. Sudhir Rao as CompuFlo® Development Partner and Advisor
16/09/2026 -
Cerenome Appoints Samantha Fowlkes as Vice President and Head of Commercial Sales, CNSide Diagnostics Division
16/09/2026 -
Artelo Biosciences Announces ART27.13 Achieved Weight Loss Comparable to Semaglutide as a Monotherapy and Doubled Weight Loss in Combination with Semaglutide in a Nonclinical Model of Obesity
16/09/2026 -
Ennature Biopharma Advances Women’s Health Science With Fast-Acting Shatavari and Sustained-Release Ginger
16/09/2026 -
Grey Matters Announces an Increase to its Equity and Convertible Debenture Private Placement to CAD $1.1 Million
16/09/2026 -
Fate Therapeutics Selected for Four Presentations Highlighting its Off-the-Shelf CAR T-Cell Portfolio in Autoimmune Disease at ACR Convergence 2026
16/09/2026 -
Coave Therapeutics Strengthens Leadership Team to Advance Lead Gene Therapy Program into the Clinic
16/09/2026 -
Sironax Announces Option Exercise and Asset Purchase
16/09/2026 -
NeurAxis to Participate in the Lytham Partners Fall 2026 Investor Conference
16/09/2026 -
Shock Top and Spirit Halloween Brew Up a Scary Good Collaboration
16/09/2026
Pages